Jpmorgan Chase & CO Nuvectis Pharma, Inc. Transaction History
Jpmorgan Chase & CO
- $1.51 Trillion
- Q3 2025
A detailed history of Jpmorgan Chase & CO transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 5,317 shares of NVCT stock, worth $32,008. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,317
Previous 5,317
-0.0%
Holding current value
$32,008
Previous $32,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding NVCT
# of Institutions
54Shares Held
3.62MCall Options Held
97.7KPut Options Held
0-
Vanguard Group Inc Valley Forge, PA699KShares$4.21 Million0.0% of portfolio
-
Ronit Capital LLP563KShares$3.39 Million5.37% of portfolio
-
Iridian Asset Management LLC406KShares$2.44 Million1.02% of portfolio
-
Baldwin Brothers LLC350KShares$2.11 Million0.15% of portfolio
-
Geode Capital Management, LLC Boston, MA326KShares$1.96 Million0.0% of portfolio
About Nuvectis Pharma, Inc.
- Ticker NVCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,642,500
- Market Cap $88.1M
- Description
- Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...